Trevena, Inc. (TRVN): Price and Financial Metrics


Trevena, Inc. (TRVN): $1.58

-0.10 (-5.95%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add TRVN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

TRVN POWR Grades

  • TRVN scores best on the Sentiment dimension, with a Sentiment rank ahead of 88.98% of US stocks.
  • TRVN's strongest trending metric is Stability; it's been moving down over the last 27 days.
  • TRVN's current lowest rank is in the Value metric (where it is better than 7.61% of US stocks).

TRVN Stock Summary

  • TRVN has a market capitalization of $11,671,711 -- more than approximately merely 3.37% of US stocks.
  • As for revenue growth, note that TRVN's revenue has grown -165.78% over the past 12 months; that beats the revenue growth of just 0.33% of US companies in our set.
  • The volatility of TREVENA INC's share price is greater than that of 99.12% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to TRVN, based on their financial statements, market capitalization, and price volatility, are AYRO, CTSO, SONM, SQL, and FCEL.
  • TRVN's SEC filings can be seen here. And to visit TREVENA INC's official web site, go to www.trevena.com.

TRVN Valuation Summary

  • In comparison to the median Healthcare stock, TRVN's price/sales ratio is 1428.57% lower, now standing at -27.9.
  • Over the past 110 months, TRVN's EV/EBIT ratio has gone up 6.4.

Below are key valuation metrics over time for TRVN.

Stock Date P/S P/B P/E EV/EBIT
TRVN 2023-01-30 -27.9 0.5 -0.2 0.1
TRVN 2023-01-27 -28.4 0.5 -0.2 0.1
TRVN 2023-01-26 -28.6 0.5 -0.2 0.1
TRVN 2023-01-25 -30.1 0.6 -0.2 0.1
TRVN 2023-01-24 -30.3 0.6 -0.2 0.1
TRVN 2023-01-23 -31.5 0.6 -0.2 0.1

TRVN Growth Metrics

    Its 2 year net cashflow from operations growth rate is now at -145.28%.
  • The year over year net income to common stockholders growth rate now stands at -73.61%.
  • The 3 year cash and equivalents growth rate now stands at 131.73%.
Over the past 15 months, TRVN's revenue has gone down $3,875,000.

The table below shows TRVN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 -0.419 -53.429 -60.618
2022-06-30 0.2 -54.736 -59.094
2022-03-31 0.378 -54.457 -58.135
2021-12-31 0.567 -50.197 -51.588
2021-09-30 0.637 -44.713 -49.506
2021-06-30 3.456 -35.523 -41.286

TRVN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • TRVN has a Quality Grade of C, ranking ahead of 33.81% of graded US stocks.
  • TRVN's asset turnover comes in at 0.029 -- ranking 357th of 680 Pharmaceutical Products stocks.
  • SIGA, FBRX, and INFI are the stocks whose asset turnover ratios are most correlated with TRVN.

The table below shows TRVN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.029 0.826 -3.505
2021-03-31 0.030 0.895 -2.700
2020-12-31 0.035 0.941 -2.283
2020-09-30 0.044 1.000 -1.557
2020-06-30 0.001 1.000 -1.390
2020-03-31 0.001 1.000 -0.927

TRVN Price Target

For more insight on analysts targets of TRVN, see our TRVN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $5.25 Average Broker Recommendation 1.62 (Moderate Buy)

TRVN Stock Price Chart Interactive Chart >

Price chart for TRVN

TRVN Price/Volume Stats

Current price $1.58 52-week high $15.28
Prev. close $1.68 52-week low $1.30
Day low $1.54 Volume 242,200
Day high $1.73 Avg. volume 98,991
50-day MA $2.08 Dividend yield N/A
200-day MA $5.31 Market Cap 10.98M

Trevena, Inc. (TRVN) Company Bio


Trevena Inc. is a clinical stage biopharmaceutical company focused on the discovery, development, and intent to commercialize therapeutics for G protein coupled receptors. The company was founded in 2007 and is based in King of Prussia, Pennsylvania.


TRVN Latest News Stream


Event/Time News Detail
Loading, please wait...

TRVN Latest Social Stream


Loading social stream, please wait...

View Full TRVN Social Stream

Latest TRVN News From Around the Web

Below are the latest news stories about TREVENA INC that investors may wish to consider to help them evaluate TRVN as an investment opportunity.

Trevena Announces Poster Presentations of TRV045 Nonclinical Epilepsy Data, and OLINVYK Clinical Neurocognitive and GI Data, at Recent Medical Meetings

TRV045 data reflected reduced seizure burden in nonclinical models of acute epilepsy presented at American College of Neuropsychopharmacology (ACNP) Annual Meeting OLINVYK poster presentation on reduced effect on neurocognitive function in humans compared to morphine presented at ACNP Annual Meeting OLINVYK comparison analysis versus other opioid treatments showed reduced gastrointestinal adverse effects presented at American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting C

Yahoo | December 8, 2022

Trevena Regains Compliance with Nasdaq Listing Requirements

CHESTERBROOK, Pa., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has received notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC (Nasdaq) by letter dated November 28, 2022 informing Trevena that it has regained compliance with the minimum bid price requirement under Nasdaq

Yahoo | November 29, 2022

Trevena, Inc. Announces $8.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

CHESTERBROOK, Pa., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) ("Trevena" or the "Company"), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 2,614,380 shares of common stock and warrants to purchase up to an aggregate of 2,614,380 share

Yahoo | November 16, 2022

JMP Securities Keeps Their Buy Rating on Trevena (TRVN)

E ratio of -0.49.

Christine Brown on TipRanks | November 9, 2022

Trevena Announces Reverse Stock Split

CHESTERBROOK, Pa., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has filed a Certificate of Amendment to its Certificate of Incorporation (the “Amendment”) to effect a reverse stock split of its common stock at a ratio of 1-for-25. The reverse stock split will become effective at 5:01 p.m. ET on Wednesd

Yahoo | November 9, 2022

Read More 'TRVN' Stories Here

TRVN Price Returns

1-mo -13.66%
3-mo -64.95%
6-mo -71.29%
1-year -87.29%
3-year -92.39%
5-year -95.84%
YTD 10.49%
2022 -90.18%
2021 -72.78%
2020 154.49%
2019 95.56%
2018 -73.13%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7831 seconds.